{"preliminary_commentary":{"by_channel":{"x_thread":3,"bluesky_thread":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT06377852","nct_id":"NCT06377852","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06377852. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Arm 1 of the study is the indicated dosing regimen, provided in the FDA approved drug label: participants will start cycle 1 with either 125mg dose of palbociclib or 600mg dose of ribociclib, in combination with endocrine therapy (AI or fulvestrant).","label":"Arm 1: Indicated Dose","type":"EXPERIMENTAL"},{"description":"Arm 2 is the titrated dosing regimen: participants will start cycle 1 with either 100 mg or 75 mg dose of palbociclib or 400 mg or 200 mg dose of ribociclib, in combination with endocrine therapy (AI or fulvestrant). For cycle 2 and for subsequent cycles, escalation to the indicated dose will be based on treatment tolerance.","label":"Arm 2: Titrated Dose","type":"EXPERIMENTAL"}],"collaborators":["Patient-Centered Outcomes Research Institute"],"completion_date":{"date":"2028-09-01","type":"ESTIMATED"},"conditions":["Metastatic Breast Cancer"],"enrollment":{"count":500,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Palbociclib 125mg","otherNames":[],"type":"DRUG"},{"name":"Ribociclib 600mg","otherNames":[],"type":"DRUG"},{"name":"Ribociclib","otherNames":[],"type":"DRUG"},{"name":"Palbociclib","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-06","lead_sponsor":"American Society of Clinical Oncology","official_title":"Comparing Oral Drug Dosing Strategies in Older Patients With Metastatic Breast Cancer to Maximize Tolerance and Reduce Discontinuation: The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2028-08-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Time to Treatment Discontinuation (TTD)","timeFrame":"up to 48 months"}],"references":[],"start_date":{"date":"2024-10-29","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study","url":"https://clinicaltrials.gov/study/NCT06377852"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06377852"}